2024
Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin
Lomakin I, Devarkar S, Grada A, Bunick C. Mechanistic Basis for the Translation Inhibition of Cutibacterium acnes by Clindamycin. Journal Of Investigative Dermatology 2024, 144: 2553-2561.e3. PMID: 39122144, DOI: 10.1016/j.jid.2024.07.013.Peer-Reviewed Original ResearchNetwork of water-mediated interactionsCutibacterium acnesPeptide bond formationNascent peptideWater-mediated interactionsTranslational inhibitionAntibiotic resistanceCryogenic electron microscopyA-resolutionMechanistic basesAntibiotic-based therapiesRRNAAminoacyl groupRibosomeAcne pathogenesisAcne therapyAntibiotic stewardshipClindamycinIncreased resistanceAcne vulgarisClinical targetsAcneAntibioticsPeptideTRNAClindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology.
Del Rosso J, Armillei M, Lomakin I, Grada A, Bunick C. Clindamycin: A Comprehensive Status Report with Emphasis on Use in Dermatology. The Journal Of Clinical And Aesthetic Dermatology 2024, 17: 29-40. PMID: 39148960, PMCID: PMC11324192.Peer-Reviewed Original ResearchAcne vulgarisTreatment of acne vulgarisApplication of clindamycinCutaneous bacterial infectionsAntibiotic treatment efficacyTopical clindamycinTopical agentsOral treatmentClindamycinSystemic agentsMultiple disease statesPharmacokinetic profileTreatment efficacyAntibiotic resistanceBacterial infectionsAntibiotic mechanismsTherapeutic valueRelevance to cliniciansDisease statesDermatologyLincosamide antibioticsAnti-inflammatoryGram-positiveAnaerobic bacteriaAcneTopical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances.
Del Rosso J, Bunick C, Kircik L, Bhatia N. Topical Clindamycin in the Management of Acne Vulgaris: Current Perspectives and Recent Therapeutic Advances. Journal Of Drugs In Dermatology 2024, 23: 438-445. PMID: 38834223, DOI: 10.36849/jdd.8318.Peer-Reviewed Original ResearchConceptsAcne vulgarisTopical clindamycinTreatment of acne vulgarisManagement of acne vulgarisEmergence of antibiotic-resistant bacteriaAntibiotic-resistant bacteriaTopical agentsAnti-inflammatory propertiesTherapeutic advancesClindamycinClinical studiesTherapeutic outcomesClinical applicationAntimicrobial profileGram-positive bacteriaAnaerobic bacteriaMode of actionVulgarisMonotherapyPublished dataBacteriaTherapyAcneAntibioticsScientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease
Armillei M, Lomakin I, Del Rosso J, Grada A, Bunick C. Scientific Rationale and Clinical Basis for Clindamycin Use in the Treatment of Dermatologic Disease. Antibiotics 2024, 13: 270. PMID: 38534705, PMCID: PMC10967556, DOI: 10.3390/antibiotics13030270.Peer-Reviewed Original ResearchSoft tissue infectionsTetracycline class antibioticsTreatment of dermatological diseasesMechanism of protein synthesis inhibitionClindamycin useStaphylococcal infectionsTissue infectionsClinical presentationAnti-inflammatory propertiesHidradenitis suppurativaEffective antibioticsTreatment optionsClindamycinClinical evidenceAcne vulgarisClinical basisProtein synthesis inhibitionDermatological indicationsAmeliorate inflammationAntibiotic resistanceDermatology practiceBacterial ribosomeDermatological diseasesClass antibioticsLesion formationAvoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations
Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s355. DOI: 10.25251/skin.8.supp.355.Peer-Reviewed Original ResearchCombination of clindamycinC. acnes strainsMinimum inhibitory concentrationCutibacterium acnesCombination of benzoyl peroxideExposure to antibioticsConcentrations of clindamycinEpsilometer testBacterial cultureDevelopment of resistanceFixed combinationMeasuring zones of inhibitionAntibiotic susceptibilityCheckerboard assayClinical strainsClindamycinAntibiotic formulationsC. acnesAntibiotic resistanceProlonged useAntibioticsZone of inhibitionAgar diffusion methodInhibitory concentrationCombination formulationAvoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations
Ghannoum M, Gamal A, Kadry A, Del Rosso J, Bunick C, Stein Gold L, Kircik L, Harper J. Avoiding the Danger of Rising Resistance in Cutibacterium acnes: Criticality of Benzoyl Peroxide and Antibiotic Fixed Combinations. SKIN The Journal Of Cutaneous Medicine 2024, 8: s354. DOI: 10.25251/skin.8.supp.354.Peer-Reviewed Original ResearchCombination of clindamycinC. acnes strainsMinimum inhibitory concentrationCutibacterium acnesCombination of benzoyl peroxideExposure to antibioticsConcentrations of clindamycinEpsilometer testBacterial cultureDevelopment of resistanceFixed combinationMeasuring zones of inhibitionAntibiotic susceptibilityCheckerboard assayClinical strainsClindamycinAntibiotic formulationsC. acnesAntibiotic resistanceProlonged useAntibioticsZone of inhibitionAgar diffusion methodInhibitory concentrationCombination formulation
2021
Treatment of Human Babesiosis: Then and Now
Renard I, Ben Mamoun C. Treatment of Human Babesiosis: Then and Now. Pathogens 2021, 10: 1120. PMID: 34578153, PMCID: PMC8469882, DOI: 10.3390/pathogens10091120.Peer-Reviewed Original ResearchHuman babesiosisSevere adverse eventsNew therapeutic strategiesPublic health concernTick-borne diseaseAdverse eventsBlood transfusionCombination therapySafe therapyRisk of humanTherapeutic strategiesHuman transmissionApicomplexan parasitesDrug resistanceHealth concernBabesiosisTherapyTreatmentDiseaseCurrent arsenalParasitesRapid emergenceTransfusionClindamycinAzithromycin
2019
Repeat exchange transfusion for treatment of severe babesiosis
Radcliffe C, Krause PJ, Grant M. Repeat exchange transfusion for treatment of severe babesiosis. Transfusion And Apheresis Science 2019, 58: 638-640. PMID: 31526674, DOI: 10.1016/j.transci.2019.07.010.Peer-Reviewed Case Reports and Technical NotesConceptsRepeat exchange transfusionExchange transfusionSevere babesiosisHospital day 5Second exchange transfusionBabesia microti infectionHigh feverRheumatoid arthritisMicroti infectionTransfusionDay 5Literature searchDearth of informationParasitemiaInfectionBabesiosisEtanerceptArthritisFeverClindamycinHypoxiaCasesWeeksWomenHuman babesiosis
Krause PJ. Human babesiosis. International Journal For Parasitology 2019, 49: 165-174. PMID: 30690090, DOI: 10.1016/j.ijpara.2018.11.007.Peer-Reviewed Original ResearchConceptsBurden of infectionSignificant health burdenNon-endemic areasTick-borne diseaseThin blood smearsBlood transfusionExchange transfusionHealth burdenSevere casesBlood smearsHuman babesiosisIntraerythrocytic parasitesTransfusionInfectionBabesiosisBurdenProtective measuresBabesia DNAClindamycinAzithromycinAtovaquoneDiseaseSmearsDiagnosis
2015
Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both?
Saifee NH, Krause PJ, Wu Y. Apheresis for babesiosis: Therapeutic parasite reduction or removal of harmful toxins or both? Journal Of Clinical Apheresis 2015, 31: 454-458. PMID: 26481763, DOI: 10.1002/jca.21429.Peer-Reviewed Original ResearchConceptsExchange transfusionHigh-risk populationLife-threatening illnessApparent therapeutic benefitBlood transfusionModerate diseaseClinical presentationAsymptomatic infectionSevere babesiosisSevere diseaseRisk populationsTherapeutic benefitTransfusionMortality rateIntraerythrocytic protozoan parasiteBabesia infectionDiseaseIxodes ticksProtozoan parasiteBabesiosisInfectionGenus BabesiaMost casesPatientsClindamycin
2008
Human Babesiosis
Vannier E, Gewurz BE, Krause PJ. Human Babesiosis. Infectious Disease Clinics Of North America 2008, 22: 469-488. PMID: 18755385, PMCID: PMC3998201, DOI: 10.1016/j.idc.2008.03.010.Peer-Reviewed Original ResearchConceptsBabesial infectionHuman babesiosisCombination of atovaquoneTreatment of choiceSpecific laboratory diagnosisModerate illnessExchange transfusionPolymerase chain reactionSevere diseaseLaboratory diagnosisMorphologic examinationBlood smearsProtozoal parasitesInfectionChain reactionBabesial DNABabesiosisIntraerythrocytic infectionUnited StatesIxodid ticksTransfusionUpper midwestern regionsClindamycinSerologyAzithromycin
2007
ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT
Raju M, Salazar JC, Leopold H, Krause PJ. ATOVAQUONE AND AZITHROMYCIN TREATMENT FOR BABESIOSIS IN AN INFANT. The Pediatric Infectious Disease Journal 2007, 26: 181-183. PMID: 17259886, DOI: 10.1097/01.inf.0000250622.11505.8f.Peer-Reviewed Original ResearchConceptsCyanotic heart diseaseBabesia microti infectionTreatment of childrenOral azithromycinThin blood smearsInitial presentationSevere anemiaHeart diseaseMicroti infectionPolymerase chain reactionHepatic enzymesBlood smearsInfantsIntraerythrocytic parasitesChain reactionTreatmentBabesiosisLaboratory testsFebrileThrombocytopeniaCyanoticAnemiaClindamycinSerologyAzithromycin
2000
Atovaquone and Azithromycin for the Treatment of Babesiosis
Krause P, Lepore T, Sikand V, Gadbaw J, Burke G, Telford S, Brassard P, Pearl D, Azlanzadeh J, Christianson D, McGrath D, Spielman A. Atovaquone and Azithromycin for the Treatment of Babesiosis. New England Journal Of Medicine 2000, 343: 1454-1458. PMID: 11078770, DOI: 10.1056/nejm200011163432004.Peer-Reviewed Original ResearchConceptsCommon adverse effectsTreatment of babesiosisAdverse reactionsAdverse effectsCourse of clindamycinRegimen of clindamycinStart of therapyMalaria-like illnessPromising alternative treatmentStandard treatmentAlternative treatmentRegimenClindamycinAzithromycinAtovaquoneMonthsDiarrheaTreatmentBabesiosisQuinineSymptomsSubjectsPercentDaysBabesia microti DNA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply